Evidence map›Paper›PMID 25893508›Full record

ArticleAnnals of biomedical engineering2015

Reducing Neointima Formation in a Swine Model with IVUS and Sirolimus Microbubbles.

Joseph P Kilroy, Ali H Dhanaliwala, Alexander L Klibanov, Douglas K Bowles, Brian R Wamhoff, John A Hossack

Abstract read
In one paragraph

Article in Annals of biomedical engineering, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Ultrasonic technologies in imaging and drug delivery.Cellular and molecular life sciences : CMLS · 2021
    Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joseph P KilroyDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, 22908, USA.
Ali H DhanaliwalaDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, 22908, USA.
Alexander L KlibanovDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, 22908, USA.
Douglas K BowlesDepartment of Veterinary Sciences, University of Missouri, Columbia, MO, USA.
Brian R WamhoffHemoShear, LLC, Charlottesville, VA, 22903, USA.
John A HossackDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, 22908, USA. jh7fj@virginia.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008715 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LAURIE, GORDON WILLIAM · 2000 to 2019
$6.6M
Molecular Targeted, Focused, Ultrasound-Based Delivery of Antiproliferative DrugsR01HL090700 · NHLBI · UNIVERSITY OF VIRGINIA · PI HOSSACK, JOHN A · 2008 to 2012
$1.8M
NHLBI NIH HHS HL090700NHLBI NIH HHS R01 HL090700NIGMS NIH HHS T32 GM007267NIGMS NIH HHS T32 GM008715NIGMS NIH HHS T32GM008715
6 · The paper itself

Abstract

Potent therapeutic compounds with dose dependent side effects require more efficient and selective drug delivery to reduce systemic drug doses. Here, we demonstrate a new platform that combines intravascular ultrasound (IVUS) and drug-loaded microbubbles to enhance and localize drug delivery, while enabling versatility of drug type and dosing. Localization and degree of delivery with IVUS and microbubbles was assessed using fluorophore-loaded microbubbles and different IVUS parameters in ex vivo swine arteries. Using a swine model of neointimal hyperplasia, reduction of neointima formation following balloon injury was evaluated when using the combination of IVUS and sirolimus-loaded microbubbles. IVUS and microbubble enhanced fluorophore delivery was greatest when applying low amplitude pulses in the ex vivo model. In the in vivo model, neointima formation was reduced by 50% after treatment with IVUS and the sirolimus-loaded microbubbles. This reduction was achieved with a sirolimus whole blood concentration comparable to a commercial drug-eluting stent (0.999 ng/mL). We anticipate this therapy will find clinical use localizing drug delivery for numerous other diseases in addition to serving as an adjunct to stents in treating atherosclerosis.

Indexed as

Drug Delivery SystemsMicrobubblesAngioplasty, Balloon, CoronaryAnimalsCoronary VesselsImmunosuppressive AgentsNeointimaSirolimusSwineUltrasonography, InterventionalImmunosuppressive AgentsSirolimusAngioplastyAtherosclerosisNeointimal hyperplasiaUltrasound

Identifiers

PMID25893508
PMCPMC4609231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.